In addition, an adolescent female with a diagnosis of refractory epilepsy was treated with anakinra first and then with canakinumab, an IL-1β antibody, during a nonconvulsive status epilepticus, which resulted in complete resolution of clinical seizures (58). Here, IL1B is linked to status epilepticus.